Publications by authors named "M Alderson"
Article Synopsis
- * The World Health Organization (WHO) is prioritizing the development of a GBS vaccine for pregnant women, aiming for vaccine licensure by 2026 as part of their 'Defeating Meningitis by 2030' initiative.
- * A Vaccine Value Profile (VVP) has been created to assess the public health, economic, and societal importance of potential GBS vaccines, with input from various experts and organizations to identify research gaps using public data. *
Background: An effective, affordable, multivalent meningococcal conjugate vaccine is needed to prevent epidemic meningitis in the African meningitis belt. Data on the safety and immunogenicity of NmCV-5, a pentavalent vaccine targeting the A, C, W, Y, and X serogroups, have been limited.
Methods: We conducted a phase 3, noninferiority trial involving healthy 2-to-29-year-olds in Mali and Gambia.
Background: Three pneumococcal conjugate vaccines (PCVs) are currently licensed and WHO prequalified for supply by UN agencies. Here, we aimed to investigate the safety and immunogenicity of SIIPL-PCV compared with PHiD-CV and PCV13, when administered to infants according to a 2 + 1 schedule.
Methods: This single-centre, double-blind, active-controlled, randomised, phase 3 trial was done in Medical Research Council Unit The Gambia at the London School of Hygiene & Tropical Medicine clinical trial facilities within two government health centres in the western region of The Gambia.
The incidence of musculoskeletal disorders (MSD) in the healthcare professional population is concerning. In particular, the high incidence of back injuries is an issue for nurses. Although many MSD prevention initiatives are being implemented, these practices are not succeeding in reducing MSDs.
View Article and Find Full Text PDF